Documents on Display
Filed with HKEX · Stock code 2509 · · Chinese
Summary by 6ix AI
This filing is a notification letter regarding documents on display for Qyuns Therapeutics Co., Ltd..
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Qyuns Therapeutics Co., Ltd. on 6ix
Earlier from Qyuns Therapeutics
- Form of proxy for the extraordinary general meeting to be held on Friday, November 13, 2026
- Notice of the 2026 first extraordinary general meeting
- (1) Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; (2) proposed appointment of director and determination of the director's remuneration; and (3) notice of the 2026 first extraordinary general meeting
- Announcement book closure period for extraordinary general meeting
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Later from Qyuns Therapeutics
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Voluntary announcement exclusive license agreement with caldera therapeutics for a preclinical bispecific antibody program targeting TL1A and IL-17
- (1) Poll results of the extraordinary general meeting held on November 13, 2026; (2) appointment of non-executive director; and (3) change in composition of board committee
- List of directors and their roles and functions
- Supplemental agreement to the CDMO services framework agreement and revision of annual cap and renewal of annual caps for continuing connected transactions
Follow Qyuns Therapeutics into a list and get an email when it puts out news.
Follow Qyuns Therapeutics